Maternal intake of paracetamol during mid-pregnancy was associated with hyperactivity and attention problems in their offspring up to preschool age, although the association was diminished as the children grew older, according to the ALSPAC* study.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
Treatment with the neurokinin-1 receptor antagonist orvepitant appears to be safe in patients with chronic refractory cough, yielding sustained improvements in cough frequency and severity, according to the results of the phase II VOLCANO-1 trial.
Use of complementary and alternative medicine (CAM) is common among patients with prostate cancer and has seen an increase among those who are newly diagnosed with the disease, a study has shown. Multivitamins and omega-3 fatty acids are the most commonly used CAMs from 1996 to 2016, while vitamin D use has increased dramatically from 2006 to 2010.
The efficacy and safety of the novel oral anticoagulant edoxaban relative to warfarin for stroke prophylaxis are consistent across the full range of systolic blood pressure (SBP) in high-risk patients with atrial fibrillation (AF), according to a posthoc analysis of the ENGAGE AF-TIMI 48 trial.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Current single-disease clinical practice guidelines (CPGs) poorly address the patient-centred care approach for older adults with multimorbidity and, when applied cumulatively, create a treatment burden that is time-consuming, costly and disruptive, according to a Singapore study.
The potent P2Y12 inhibitor prasugrel significantly reduced the incidence of death, myocardial infarction (MI), or stroke in patients with acute coronary syndrome (ACS) with or without ST-segment elevation (STE) compared with ticagrelor, according to the results of the ISAR-REACT* 5 trial presented at ESC Congress 2019. Moreover, the improved anti-ischaemic efficacy of prasugrel was not accompanied by an increased bleeding risk.
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.